Doctor and patient interacting. Credit: Canva
Lymphoma is a broad term for cancer that begins in cells of the lymphatic or immune system. B-cell lymphomas are a type of cancer that forms in B cells (a type of immune cell). A clinical trial led by Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is studying the use of CAR T-cell therapy for adult patients with relapsed or refractory large B-cell lymphoma (LBCL).
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Bonnie Yates, CRNP, at 240-760-6204 or bonnie.yates@nih.gov
Clinicaltrials.gov identifier: NCT05972720
NCI Protocol ID: IRB001783
Official Title: An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
